United States Overactive Bladder Treatment Industry Market Analysis & Forecast 2018-2023
In the United States Overactive Bladder Treatment Industry Market Analysis & Forecast 2018-2023, the revenue is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2023, growing at a CAGR of XX% between 2018 and 2023. The production is estimated at XX million in 2017 and is forecasted to reach XX million by the end of 2023, growing at a CAGR of XX% between 2018 and 2023.
It covers Regional Segment Analysis, Type, Appliction, Major Manufactures, Industry Chain Analysis, Competitive Insights and Macroeconomic Analysis.
The Major players reported in the market include:
Astellas Pharma, Inc. (Japan)
Pfizer, Inc. (U.S.)
Allergan, Plc. (Ireland)
Teva Pharmaceutical Industries Limited (Israel)
Mylan N.V. (U.S.)
Medtronic plc (Ireland)
Endo International plc (Ireland)
Sanofi (France)
Hisamitsu Pharmaceutical Co., Inc. (Japan)
United States Overactive Bladder Treatment Market: Product Segment Analysis
Idiopathic
Neurogenic Bladder Overactivity
Type 3
United States Overactive Bladder Treatment Market: Application Segment Analysis
Hospital
Clinic
Others
Reasons for Buying this Report
It covers Regional Segment Analysis, Type, Appliction, Major Manufactures, Industry Chain Analysis, Competitive Insights and Macroeconomic Analysis.
The Major players reported in the market include:
Astellas Pharma, Inc. (Japan)
Pfizer, Inc. (U.S.)
Allergan, Plc. (Ireland)
Teva Pharmaceutical Industries Limited (Israel)
Mylan N.V. (U.S.)
Medtronic plc (Ireland)
Endo International plc (Ireland)
Sanofi (France)
Hisamitsu Pharmaceutical Co., Inc. (Japan)
United States Overactive Bladder Treatment Market: Product Segment Analysis
Idiopathic
Neurogenic Bladder Overactivity
Type 3
United States Overactive Bladder Treatment Market: Application Segment Analysis
Hospital
Clinic
Others
Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
United States Overactive Bladder Treatment Industry Market Analysis & Forecast 2018-2023
CHAPTER 1 OVERACTIVE BLADDER TREATMENT MARKET OVERVIEW
1.1 Product Overview and Scope of Overactive Bladder Treatment
1.2 Overactive Bladder Treatment Market Segmentation by Type
1.2.1 United States Production Market Share of Overactive Bladder Treatment by Type in 2016
1.2.1 Idiopathic
1.2.2 Neurogenic Bladder Overactivity
1.2.3 Type
1.3 Overactive Bladder Treatment Market Segmentation by Application
1.3.1 Overactive Bladder Treatment Consumption Market Share by Application in 20156
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 United States Market Size Sales (Value) and Revenue (Volume) of Overactive Bladder Treatment (2013-2023)
CHAPTER 2 UNITED STATES ECONOMIC IMPACT ON OVERACTIVE BLADDER TREATMENT INDUSTRY
2.1 United States Macroeconomic Analysis
2.2 United States Macroeconomic Environment Development Trend
CHAPTER 3 UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET COMPETITION BY MANUFACTURERS
3.1 United States Overactive Bladder Treatment Production and Share by Manufacturers (2016 and 2017)
3.2 United States Overactive Bladder Treatment Revenue and Share by Manufacturers (2016 and 2017)
3.3 United States Overactive Bladder Treatment Average Price by Manufacturers (2016 and 2017)
3.4 Manufacturers Overactive Bladder Treatment Manufacturing Base Distribution, Production Area and Product Type
3.5 Overactive Bladder Treatment Market Competitive Situation and Trends
3.5.1 Overactive Bladder Treatment Market Concentration Rate
3.5.2 Overactive Bladder Treatment Market Share of Top 3 and Top 5 Manufacturers
3.5.3 Mergers & Acquisitions, Expansion
CHAPTER 4 UNITED STATES OVERACTIVE BLADDER TREATMENT PRODUCTION, REVENUE (VALUE), PRICE TREND BY TYPE
4.1 United States Overactive Bladder Treatment Production and Market Share by Type (2013-2018)
4.2 United States Overactive Bladder Treatment Revenue and Market Share by Type (2013-2018)
4.3 United States Overactive Bladder Treatment Price by Type (2013-2018)
4.4 United States Overactive Bladder Treatment Production Growth by Type (2013-2018)
CHAPTER 5 UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY APPLICATION
5.1 United States Overactive Bladder Treatment Consumption and Market Share by Application (2013-2018)
5.2 United States Overactive Bladder Treatment Consumption Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities
5.3.1 Potential Applications
5.3.2 Emerging Markets/Countries
CHAPTER 6 UNITED STATES OVERACTIVE BLADDER TREATMENT MANUFACTURERS ANALYSIS
6.1 Astellas Pharma, Inc. (Japan)
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Product Type, Application and Specification
6.1.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.1.4 Business Overview
6.2 Pfizer, Inc. (U.S.)
6.2.1 Company Basic Information, Manufacturing Base and Competitors
6.2.2 Product Type, Application and Specification
6.2.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.2.4 Business Overview
6.3 Allergan, Plc. (Ireland)
6.3.1 Company Basic Information, Manufacturing Base and Competitors
6.3.2 Product Type, Application and Specification
6.3.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.3.4 Business Overview
6.4 Teva Pharmaceutical Industries Limited (Israel)
6.4.1 Company Basic Information, Manufacturing Base and Competitors
6.4.2 Product Type, Application and Specification
6.4.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.4.4 Business Overview
6.5 Mylan N.V. (U.S.)
6.5.1 Company Basic Information, Manufacturing Base and Competitors
6.5.2 Product Type, Application and Specification
6.5.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.5.4 Business Overview
6.6 Medtronic plc (Ireland)
6.6.1 Company Basic Information, Manufacturing Base and Competitors
6.6.2 Product Type, Application and Specification
6.6.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.6.4 Business Overview
6.7 Endo International plc (Ireland)
6.7.1 Company Basic Information, Manufacturing Base and Competitors
6.7.2 Product Type, Application and Specification
6.7.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.7.4 Business Overview
6.8 Sanofi (France)
6.6.1 Company Basic Information, Manufacturing Base and Competitors
6.6.2 Product Type, Application and Specification
6.6.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.6.4 Business Overview
6.9 Hisamitsu Pharmaceutical Co., Inc. (Japan)
6.9.1 Company Basic Information, Manufacturing Base and Competitors
6.9.2 Product Type, Application and Specification
6.9.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.9.4 Business Overview
…
CHAPTER 7 OVERACTIVE BLADDER TREATMENT MANUFACTURING COST ANALYSIS
7.1 Overactive Bladder Treatment Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Overactive Bladder Treatment
CHAPTER 8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS
8.1 Overactive Bladder Treatment Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Overactive Bladder Treatment Major Manufacturers in 2016
8.4 Downstream Buyers
CHAPTER 9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
CHAPTER 10 MARKET EFFECT FACTORS ANALYSIS
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
CHAPTER 11 UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET FORECAST (2018-2013)
11.1 United States Overactive Bladder Treatment Production, Revenue Forecast (2018-2013)
11.2 United States Overactive Bladder Treatment Production, Consumption Forecast by Regions (2018-2013)
11.3 United States Overactive Bladder Treatment Production Forecast by Type (2018-2013)
11.4 United States Overactive Bladder Treatment Consumption Forecast by Application (2018-2013)
11.5 Overactive Bladder Treatment Price Forecast (2018-2013)
CHAPTER 12 APPENDIX
CHAPTER 1 OVERACTIVE BLADDER TREATMENT MARKET OVERVIEW
1.1 Product Overview and Scope of Overactive Bladder Treatment
1.2 Overactive Bladder Treatment Market Segmentation by Type
1.2.1 United States Production Market Share of Overactive Bladder Treatment by Type in 2016
1.2.1 Idiopathic
1.2.2 Neurogenic Bladder Overactivity
1.2.3 Type
1.3 Overactive Bladder Treatment Market Segmentation by Application
1.3.1 Overactive Bladder Treatment Consumption Market Share by Application in 20156
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 United States Market Size Sales (Value) and Revenue (Volume) of Overactive Bladder Treatment (2013-2023)
CHAPTER 2 UNITED STATES ECONOMIC IMPACT ON OVERACTIVE BLADDER TREATMENT INDUSTRY
2.1 United States Macroeconomic Analysis
2.2 United States Macroeconomic Environment Development Trend
CHAPTER 3 UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET COMPETITION BY MANUFACTURERS
3.1 United States Overactive Bladder Treatment Production and Share by Manufacturers (2016 and 2017)
3.2 United States Overactive Bladder Treatment Revenue and Share by Manufacturers (2016 and 2017)
3.3 United States Overactive Bladder Treatment Average Price by Manufacturers (2016 and 2017)
3.4 Manufacturers Overactive Bladder Treatment Manufacturing Base Distribution, Production Area and Product Type
3.5 Overactive Bladder Treatment Market Competitive Situation and Trends
3.5.1 Overactive Bladder Treatment Market Concentration Rate
3.5.2 Overactive Bladder Treatment Market Share of Top 3 and Top 5 Manufacturers
3.5.3 Mergers & Acquisitions, Expansion
CHAPTER 4 UNITED STATES OVERACTIVE BLADDER TREATMENT PRODUCTION, REVENUE (VALUE), PRICE TREND BY TYPE
4.1 United States Overactive Bladder Treatment Production and Market Share by Type (2013-2018)
4.2 United States Overactive Bladder Treatment Revenue and Market Share by Type (2013-2018)
4.3 United States Overactive Bladder Treatment Price by Type (2013-2018)
4.4 United States Overactive Bladder Treatment Production Growth by Type (2013-2018)
CHAPTER 5 UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY APPLICATION
5.1 United States Overactive Bladder Treatment Consumption and Market Share by Application (2013-2018)
5.2 United States Overactive Bladder Treatment Consumption Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities
5.3.1 Potential Applications
5.3.2 Emerging Markets/Countries
CHAPTER 6 UNITED STATES OVERACTIVE BLADDER TREATMENT MANUFACTURERS ANALYSIS
6.1 Astellas Pharma, Inc. (Japan)
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Product Type, Application and Specification
6.1.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.1.4 Business Overview
6.2 Pfizer, Inc. (U.S.)
6.2.1 Company Basic Information, Manufacturing Base and Competitors
6.2.2 Product Type, Application and Specification
6.2.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.2.4 Business Overview
6.3 Allergan, Plc. (Ireland)
6.3.1 Company Basic Information, Manufacturing Base and Competitors
6.3.2 Product Type, Application and Specification
6.3.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.3.4 Business Overview
6.4 Teva Pharmaceutical Industries Limited (Israel)
6.4.1 Company Basic Information, Manufacturing Base and Competitors
6.4.2 Product Type, Application and Specification
6.4.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.4.4 Business Overview
6.5 Mylan N.V. (U.S.)
6.5.1 Company Basic Information, Manufacturing Base and Competitors
6.5.2 Product Type, Application and Specification
6.5.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.5.4 Business Overview
6.6 Medtronic plc (Ireland)
6.6.1 Company Basic Information, Manufacturing Base and Competitors
6.6.2 Product Type, Application and Specification
6.6.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.6.4 Business Overview
6.7 Endo International plc (Ireland)
6.7.1 Company Basic Information, Manufacturing Base and Competitors
6.7.2 Product Type, Application and Specification
6.7.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.7.4 Business Overview
6.8 Sanofi (France)
6.6.1 Company Basic Information, Manufacturing Base and Competitors
6.6.2 Product Type, Application and Specification
6.6.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.6.4 Business Overview
6.9 Hisamitsu Pharmaceutical Co., Inc. (Japan)
6.9.1 Company Basic Information, Manufacturing Base and Competitors
6.9.2 Product Type, Application and Specification
6.9.3 Production, Revenue, Price and Gross Margin (2013-2018)
6.9.4 Business Overview
…
CHAPTER 7 OVERACTIVE BLADDER TREATMENT MANUFACTURING COST ANALYSIS
7.1 Overactive Bladder Treatment Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Overactive Bladder Treatment
CHAPTER 8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS
8.1 Overactive Bladder Treatment Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Overactive Bladder Treatment Major Manufacturers in 2016
8.4 Downstream Buyers
CHAPTER 9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
CHAPTER 10 MARKET EFFECT FACTORS ANALYSIS
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
CHAPTER 11 UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET FORECAST (2018-2013)
11.1 United States Overactive Bladder Treatment Production, Revenue Forecast (2018-2013)
11.2 United States Overactive Bladder Treatment Production, Consumption Forecast by Regions (2018-2013)
11.3 United States Overactive Bladder Treatment Production Forecast by Type (2018-2013)
11.4 United States Overactive Bladder Treatment Consumption Forecast by Application (2018-2013)
11.5 Overactive Bladder Treatment Price Forecast (2018-2013)
CHAPTER 12 APPENDIX
LIST OF TABLES AND FIGURES
Figure Picture of Overactive Bladder Treatment
Table Classification of Overactive Bladder Treatment
Figure United States Sales Market Share of Overactive Bladder Treatment by Type in 2016
Table Application of Overactive Bladder Treatment
Figure United States Sales Market Share of Overactive Bladder Treatment by Application in 2016
Figure United States Overactive Bladder Treatment Sales and Growth Rate (2013-2023)
Figure United States Overactive Bladder Treatment Revenue and Growth Rate (2013-2023)
Table United States Overactive Bladder Treatment Sales of Key Manufacturers (2016 and 2017)
Table United States Overactive Bladder Treatment Sales Share by Manufacturers (2016 and 2017)
Figure 2015 Overactive Bladder Treatment Sales Share by Manufacturers
Figure 2016 Overactive Bladder Treatment Sales Share by Manufacturers
Table United States Overactive Bladder Treatment Revenue by Manufacturers (2016 and 2017)
Table United States Overactive Bladder Treatment Revenue Share by Manufacturers (2016 and 2017)
Table 2015 United States Overactive Bladder Treatment Revenue Share by Manufacturers
Table 2016 United States Overactive Bladder Treatment Revenue Share by Manufacturers
Table United States Market Overactive Bladder Treatment Average Price of Key Manufacturers (2016 and 2017)
Figure United States Market Overactive Bladder Treatment Average Price of Key Manufacturers in 2016
Figure Overactive Bladder Treatment Market Share of Top 3 Manufacturers
Figure Overactive Bladder Treatment Market Share of Top 5 Manufacturers
Table United States Overactive Bladder Treatment Sales by Type (2013-2018)
Table United States Overactive Bladder Treatment Sales Share by Type (2013-2018)
Figure United States Overactive Bladder Treatment Sales Market Share by Type in 2016
Table United States Overactive Bladder Treatment Revenue and Market Share by Type (2013-2018)
Table United States Overactive Bladder Treatment Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Overactive Bladder Treatment by Type (2013-2018)
Table United States Overactive Bladder Treatment Price by Type (2013-2018)
Figure United States Overactive Bladder Treatment Sales Growth Rate by Type (2013-2018)
Table United States Overactive Bladder Treatment Sales by Application (2013-2018)
Table United States Overactive Bladder Treatment Sales Market Share by Application (2013-2018)
Figure United States Overactive Bladder Treatment Sales Market Share by Application in 2015
Table United States Overactive Bladder Treatment Sales Growth Rate by Application (2013-2018)
Figure United States Overactive Bladder Treatment Sales Growth Rate by Application (2013-2018)
Table Astellas Pharma, Inc. (Japan) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Astellas Pharma, Inc. (Japan) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Astellas Pharma, Inc. (Japan) Overactive Bladder Treatment Market Share (2013-2018)
Table Pfizer, Inc. (U.S.) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Pfizer, Inc. (U.S.) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Pfizer, Inc. (U.S.) Overactive Bladder Treatment Market Share (2013-2018)
Table Allergan, Plc. (Ireland) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Allergan, Plc. (Ireland) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Allergan, Plc. (Ireland) Overactive Bladder Treatment Market Share (2013-2018)
Table Teva Pharmaceutical Industries Limited (Israel) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Treatment Market Share (2013-2018)
Table Mylan N.V. (U.S.) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Mylan N.V. (U.S.) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Mylan N.V. (U.S.) Overactive Bladder Treatment Market Share (2013-2018)
Table Medtronic plc (Ireland) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Medtronic plc (Ireland) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Medtronic plc (Ireland) Overactive Bladder Treatment Market Share (2013-2018)
Table Endo International plc (Ireland) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Endo International plc (Ireland) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Endo International plc (Ireland) Overactive Bladder Treatment Market Share (2013-2018)
Table Sanofi (France) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Sanofi (France) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Sanofi (France) Overactive Bladder Treatment Market Share (2013-2018)
Table Hisamitsu Pharmaceutical Co., Inc. (Japan) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Treatment Market Share (2013-2018)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Overactive Bladder Treatment
Figure Manufacturing Process Analysis of Overactive Bladder Treatment
Figure Overactive Bladder Treatment Industrial Chain Analysis
Table Raw Materials Sources of Overactive Bladder Treatment Major Manufacturers in 2016
Table Major Buyers of Overactive Bladder Treatment
Table Distributors/Traders List
Figure United States Overactive Bladder Treatment Production and Growth Rate Forecast (2018-2013)
Figure United States Overactive Bladder Treatment Revenue and Growth Rate Forecast (2018-2013)
Table United States Overactive Bladder Treatment Production Forecast by Type (2018-2013)
Table United States Overactive Bladder Treatment Consumption Forecast by Application (2018-2013)
COMPANIES MENTIONED
Astellas Pharma, Inc. (Japan) Pfizer, Inc. (U.S.) Allergan, Plc. (Ireland) Teva Pharmaceutical Industries Limited (Israel) Mylan N.V. (U.S.) Medtronic plc (Ireland) Endo International plc (Ireland) Sanofi (France) Hisamitsu Pharmaceutical Co., Inc. (Japan)
Figure Picture of Overactive Bladder Treatment
Table Classification of Overactive Bladder Treatment
Figure United States Sales Market Share of Overactive Bladder Treatment by Type in 2016
Table Application of Overactive Bladder Treatment
Figure United States Sales Market Share of Overactive Bladder Treatment by Application in 2016
Figure United States Overactive Bladder Treatment Sales and Growth Rate (2013-2023)
Figure United States Overactive Bladder Treatment Revenue and Growth Rate (2013-2023)
Table United States Overactive Bladder Treatment Sales of Key Manufacturers (2016 and 2017)
Table United States Overactive Bladder Treatment Sales Share by Manufacturers (2016 and 2017)
Figure 2015 Overactive Bladder Treatment Sales Share by Manufacturers
Figure 2016 Overactive Bladder Treatment Sales Share by Manufacturers
Table United States Overactive Bladder Treatment Revenue by Manufacturers (2016 and 2017)
Table United States Overactive Bladder Treatment Revenue Share by Manufacturers (2016 and 2017)
Table 2015 United States Overactive Bladder Treatment Revenue Share by Manufacturers
Table 2016 United States Overactive Bladder Treatment Revenue Share by Manufacturers
Table United States Market Overactive Bladder Treatment Average Price of Key Manufacturers (2016 and 2017)
Figure United States Market Overactive Bladder Treatment Average Price of Key Manufacturers in 2016
Figure Overactive Bladder Treatment Market Share of Top 3 Manufacturers
Figure Overactive Bladder Treatment Market Share of Top 5 Manufacturers
Table United States Overactive Bladder Treatment Sales by Type (2013-2018)
Table United States Overactive Bladder Treatment Sales Share by Type (2013-2018)
Figure United States Overactive Bladder Treatment Sales Market Share by Type in 2016
Table United States Overactive Bladder Treatment Revenue and Market Share by Type (2013-2018)
Table United States Overactive Bladder Treatment Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Overactive Bladder Treatment by Type (2013-2018)
Table United States Overactive Bladder Treatment Price by Type (2013-2018)
Figure United States Overactive Bladder Treatment Sales Growth Rate by Type (2013-2018)
Table United States Overactive Bladder Treatment Sales by Application (2013-2018)
Table United States Overactive Bladder Treatment Sales Market Share by Application (2013-2018)
Figure United States Overactive Bladder Treatment Sales Market Share by Application in 2015
Table United States Overactive Bladder Treatment Sales Growth Rate by Application (2013-2018)
Figure United States Overactive Bladder Treatment Sales Growth Rate by Application (2013-2018)
Table Astellas Pharma, Inc. (Japan) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Astellas Pharma, Inc. (Japan) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Astellas Pharma, Inc. (Japan) Overactive Bladder Treatment Market Share (2013-2018)
Table Pfizer, Inc. (U.S.) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Pfizer, Inc. (U.S.) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Pfizer, Inc. (U.S.) Overactive Bladder Treatment Market Share (2013-2018)
Table Allergan, Plc. (Ireland) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Allergan, Plc. (Ireland) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Allergan, Plc. (Ireland) Overactive Bladder Treatment Market Share (2013-2018)
Table Teva Pharmaceutical Industries Limited (Israel) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Treatment Market Share (2013-2018)
Table Mylan N.V. (U.S.) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Mylan N.V. (U.S.) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Mylan N.V. (U.S.) Overactive Bladder Treatment Market Share (2013-2018)
Table Medtronic plc (Ireland) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Medtronic plc (Ireland) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Medtronic plc (Ireland) Overactive Bladder Treatment Market Share (2013-2018)
Table Endo International plc (Ireland) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Endo International plc (Ireland) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Endo International plc (Ireland) Overactive Bladder Treatment Market Share (2013-2018)
Table Sanofi (France) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Sanofi (France) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Sanofi (France) Overactive Bladder Treatment Market Share (2013-2018)
Table Hisamitsu Pharmaceutical Co., Inc. (Japan) Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Treatment Production, Revenue, Price and Gross Margin (2013-2018)
Table Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Treatment Market Share (2013-2018)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Overactive Bladder Treatment
Figure Manufacturing Process Analysis of Overactive Bladder Treatment
Figure Overactive Bladder Treatment Industrial Chain Analysis
Table Raw Materials Sources of Overactive Bladder Treatment Major Manufacturers in 2016
Table Major Buyers of Overactive Bladder Treatment
Table Distributors/Traders List
Figure United States Overactive Bladder Treatment Production and Growth Rate Forecast (2018-2013)
Figure United States Overactive Bladder Treatment Revenue and Growth Rate Forecast (2018-2013)
Table United States Overactive Bladder Treatment Production Forecast by Type (2018-2013)
Table United States Overactive Bladder Treatment Consumption Forecast by Application (2018-2013)
COMPANIES MENTIONED
Astellas Pharma, Inc. (Japan) Pfizer, Inc. (U.S.) Allergan, Plc. (Ireland) Teva Pharmaceutical Industries Limited (Israel) Mylan N.V. (U.S.) Medtronic plc (Ireland) Endo International plc (Ireland) Sanofi (France) Hisamitsu Pharmaceutical Co., Inc. (Japan)
